Integra D
Posted Date: May 15, 2025
- Investigator: Srinivas Rajsheker
- Specialties:
- Type of Study: Device
The trial will evaluate a combination device (a cardiac contractility modulator [CCM] and defibrillator) in patients with HFrEF, who often have an indication for both therapies. CCM is a device-based therapy for HFrEF that involves applying relatively high-voltage, long-duration, biphasic electric signals to the right ventricular septal wall during the absolute myocardial refractory period. Accordingly, CCM signals do not elicit a new contraction; rather, they influence the biology of the failing myocardium. CCM signals have been shown to induce an acute, mild augmentation of left ventricular (LV) contractile strength without an increase in myocardial oxygen consumption. CCM is currently approved for HFrEF patients who are symptomatic and are not eligible for chronic resynchronization therapy.
Criteria:
Patients With Ymptomatic Heart Failure From Either Non-Ischemic Cardiomyopathy Or Ischemic Cardiomyopathy
Keywords:
Cardiac Contractility Modulator In Hfref
For More Information:
Jill Schulte
513-558-3415
schultj4@ucmail.uc.edu